Adalimumab is effective uveitis treatment

Article

Adalimumab is an effective treatment for patients with active non-infectious uveitis, according to a recent investigation.

Adalimumab is an effective treatment for patients with active non-infectious uveitis, according to a recent investigation.

Dr Bianca Carola Dobner et al., Department of Ophthalmology, Interdisciplinary Uveitis Centre, University of Heidelberg, Heidelberg, Germany, conducted a retrospective study on 60 patients who were treated with adalimumab.

Outcome measures for efficacy were reduction of macular oedema by optic coherence tomography, visual acuity, anterior chamber cells, reduction of frequency of flares and reduction of prednisone dose during the treatment.

Of the patients assessed, 49 improved while the remaining 11 were administered additional or alternative immunosuppressive treatment. At the last follow-up 47 patients still received adalimumab treatment.

Side effects, including liver enzyme elevation and furunculosis, occurred in three patients. Treatment was stopped in 13 patients due to inefficacy, in three patients due to side effects, one pregnant patient and one patient who died.

Overall, the results of this study demonstrated that adalimumab is effective for the treatment of uveitis in up to 80% of patients. To read the abstract please visit the British Journal of Ophthalmology.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.